MHRA Approves Dysport for Upper Limb Spasticity in Children

January 14, 2020

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Ipsen Pharmaceuticals’ Dysport (clostridium botulinum type A toxin-haemagglutinin complex) for the symptomatic treatment upper limb spasticity in pediatric cerebral palsy patients two years of age and older.

The approval was based on a phase 3 clinical trial which demonstrated that Dysport reduced spasticity symptoms in children being treated for upper limb spasticity due to cerebral palsy.

Dysport is the first botulinum toxin to be approved in the UK for the treatment of pediatric spasticity in both upper and lower limbs.

View today's stories